The blockbuster success of Novo Nordisks Ozempic/Wegovy and Lillys Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer
The peptide is not damaged
Our findings, supported by propensity score matching between study and control groups, indicated an approximate 10% increase in oocyte maturation rate, normal fertilization rate, and blastocyst formation rate, along with a 5% rise in the usable blastocyst rate
The drug also causes rapid weight loss for some people, which can lead to significant muscle mass loss and sagging skin, which is most noticeable in the face
Reporting helps protect other patients and supports ongoing regulatory oversight
The optimal syringe choice varies accordingly